Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: An important variable to be considered in clinical trial designs

Cancer

Volumn 112, Issue 12, 2008, Pages 2720-2725

  Barlogie, Bart ^a,c   Haessler, Jeff ^b   Pineda Roman, Mauricio ^a   Anaissie, Elias ^a   Van Rhee, Frits ^a   Kiwan, Elias ^a   Steward, Douglas ^a   Gurley, Jennifer ^a   Jenkins, Bonnie ^a   Crowley, John ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NONE   (United States)

Author keywords

Completion of therapy; Event free survival; Overall survival; Total therapy

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; C REACTIVE PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERFERON; M PROTEIN; MELPHALAN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION PROFILING; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPOALBUMINEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; REMISSION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; RESEARCH DESIGN; SURVIVAL RATE;

EID: 46049106797     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23487     Document Type: Article

References (16)

1. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
2. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
3. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
4. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation in multiple myeloma. N Engl J Med. 2006;354:1021-1030.
5. van Rhee F, Bloejack V, Hollmig K, et al. High serum free-light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827-832.
6. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3. Br J Haematol. 2007;138:176-185.
7. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in Total Therapy 3: comparison with Total Therapy 2. Br J Haematol. 2007;136:393-399.
8. Sawyer J, Waldron 7, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-49.
9. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
10. Shaughnessy JD Jr, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
11. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
14. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187-202.
15. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-831.
16. Palumbo A, Ambrosini T, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767-2772.